Table 1: Clinical features of all patients with and without CSVT.

Variables		CSVT		*p*-value
		No **N=205**	**Yes** **N=24**	
Gender	Male	117 (57.1%)	21 (87.5%)	**0.004**
	Female	88 (42.9%)	3 (12.5%)	
Age at Diagnosis	Mean (± SD)	6.3 ± 4.7	10.2 ± 4.7	**<0.0001**
	<10	154 (75.1%)	11 (45.8%)	**0.002**
	≥10	51 (24.9%)	13 (54.2%)	
Phenotype	B	177 (86.3%)	10 (41.7%)	**<0.0001**
	T	28 (13.7%)	14 (58.3%)	
Risk	Low	106 (51.7%)	8 (33.3%)	**0.05**
	High/standard	99 (48.3%)	16 (66.7%)	
Max TG level*	<615	127 (74.3%)	8 (44.4%)	**0.012**
	≥615	44 (25.7%)	10 (55.6%)	
Mediastinal Mass	Yes	15 (7.3%)	11 (45.8%)	**<0.0001**
	No	190 (92.7%)	13 (54.2%)	
Initial Blasts	Mean (± SD)	28714 ± 68119	28021 ± 55536	0.96
	<10000	136 (66.3%)	17 (70.8%)	0.765
	10000-50000	38 (18.5%)	3 (12.5%)	
	>500000	31 (15.1%)	4 (16.7%)	
BMI* (kg/m^2)	Mean (± SD)	17.9841 ± 9.63414	20.5706 ± 5.77814	0.209
BSA (m^2)**	Mean (± SD)	0.9210 ± 0.42238	1.3313 ± 0.50235	**<0.0001**
Blood Group	O	63 (31.3%)	8 (33.3%)	0.843
	Non-O	138 (68.7%)	16 (66.6%)	

*Body Mass Index (kg/m^2)
**Body Surface Area (m^2)
***Maximal triglycerides level during induction or reinduction of treatment
The risk stratification of patients was defined as per the low vs. standard/high risk protocol.
The initial blast count was calculated as the percentage of blasts multiplied by the

total white blood cells upon presentation of patients